Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

Heart Failure Reviews

Volumn 17, Issue 4-5, 2012, Pages 693-706

  Moore, Linn ^a   Fan, Dong ^a   Basu, Ratnadeep ^a   Kandalam, Vijay ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Extracellular matrix; Heart failure; Matrix metalloproteinases; Remodeling; Tissue inhibitor of metalloproteinases

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PG 11680; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AORTA STENOSIS; CARDITIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISULFIDE BOND; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART VENTRICLE REMODELING; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 84862676645     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9266-y     Document Type: Review

References (148)

1. SA Hunt WT Abraham MH Chin, et al. 2005 ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 e154 e235 16160202
2. YY Li CF McTiernan AM Feldman 2000 Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling Cardiovasc Res 46 214 224 10773225 1:CAS:528:DC%2BD3cXisFGru70%3D
3. FG Spinale 2007 Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 1285 1342 17928585 1:CAS:528:DC%2BD2sXhtlaqu7vF
4. FG Spinale NM Wilbur 2009 Matrix metalloproteinase therapy in heart failure Curr Treat Options Cardiovasc Med 11 339 346 19627666
5. RS Ross TK Borg 2001 Integrins and the myocardium Circ Res 88 1112 1119 11397776 1:CAS:528:DC%2BD3MXksVejtLg%3D
6. AM Manso L Elsherif SM Kang, et al. 2006 Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling Cardiovasc Res 69 574 584 16253214 1:CAS:528:DC%2BD28XotVKitw%3D%3D
7. W Carver I Molano TA Reaves, et al. 1995 Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts J Cell Physiol 165 425 437 7593221 1:CAS:528:DyaK2MXptVWmurg%3D
8. M Hyytiainen C Penttinen J Keski-Oja 2004 Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation Crit Rev Clin Lab Sci 41 233 264 15307633
9. DL Mann FG Spinale 1998 Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds Circulation 98 1699 1702 9788821 1:STN:280:DyaK1M%2FgsFequg%3D%3D
10. D Kelly S Khan G Cockerill, et al. 2008 Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction Eur J Heart Fail 10 133 139 18234553 1:CAS:528:DC%2BD1cXitVentbw%3D
11. MV Barbolina MS Stack 2008 Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis Semin Cell Dev Biol 19 24 33 17702616 1:CAS:528:DC%2BD2sXhsVeqtLnE
12. T Takino H Saeki H Miyamori, et al. 2007 Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions Cancer Res 67 11621 11629 18089791 1:CAS:528:DC%2BD2sXhsVCjs7rJ
13. XM Shen YP Wu YB Feng, et al. 2007 Interaction of MT1-MMP and laminin-5gamma2 chain correlates with metastasis and invasiveness in human esophageal squamous cell carcinoma Clin Exp Metastasis 24 541 550 17668281 1:CAS:528:DC%2BD2sXhsVKntLjF
14. B Steffensen UM Wallon CM Overall 1995 Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen J Biol Chem 270 11555 11566 7744795 1:CAS:528:DyaK2MXls1eisb4%3D
15. MP Vincenti CI Coon JA Mengshol, et al. 1998 Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1) Biochem J 331 Pt 1 341 346 9512498 1:CAS:528: DyaK1cXisVWktLk%3D
16. RK Nuttall CL Sampieri CJ Pennington, et al. 2004 Expression analysis of the entire MMP and TIMP gene families during mouse tissue development FEBS Lett 563 129 134 15063736 1:CAS:528:DC%2BD2cXivVGhu7k%3D
17. AH Baker DR Edwards G Murphy 2002 Metalloproteinase inhibitors: biological actions and therapeutic opportunities J Cell Sci 115 3719 3727 12235282 1:CAS:528:DC%2BD38XotFemtbs%3D
18. Melendez-Zajgla J, Del Pozo L, Ceballos G et al. (2008) Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer 7:85
19. MJ Santos-Martinez C Medina P Jurasz, et al. 2008 Role of metalloproteinases in platelet function Thromb Res 121 535 542 17681591 1:CAS:528:DC%2BD1cXhsFylsrw%3D
20. L Sottrup-Jensen H Birkedal-Hansen 1989 Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins J Biol Chem 264 393 401 2462561 1:CAS:528:DyaL1MXltlGmtw%3D%3D
21. J Oh R Takahashi S Kondo, et al. 2001 The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis Cell 107 789 800 11747814 1:CAS:528:DC%2BD38XhtFymuw%3D%3D
22. J Oh DW Seo T Diaz, et al. 2004 Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK Cancer Res 64 9062 9069 15604273 1:CAS:528:DC%2BD2cXhtVOmsLnL
23. A Tuuttila E Morgunova U Bergmann, et al. 1998 Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution J Mol Biol 284 1133 1140 9837731 1:CAS:528:DyaK1MXivFCgtw%3D%3D
24. DA Douglas YE Shi QA Sang 1997 Computational sequence analysis of the tissue inhibitor of metalloproteinase family J Protein Chem 16 237 255 9188064 1:CAS:528:DyaK2sXjvVamtLc%3D
25. SS Apte BR Olsen G Murphy 1995 The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family J Biol Chem 270 14313 14318 7782289 1:CAS:528: DyaK2MXmsVSisbw%3D
26. KP Langton MD Barker N McKie 1998 Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation J Biol Chem 273 16778 16781 9642234 1:CAS:528:DyaK1cXkt12nurg%3D
27. NC Caterina LJ Windsor MK Bodden, et al. 1998 Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1) Biochim Biophys Acta 1388 21 34 9774703 1:CAS:528:DyaK1cXms1Srsbc%3D
28. JW Dennis M Granovsky CE Warren 1999 Protein glycosylation in development and disease Bioessays 21 412 421 10376012 1:STN:280:DyaK1MzgsVejsg%3D%3D
29. RE Stroud AM Deschamps AS Lowry, et al. 2005 Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy J Card Fail 11 124 130 15732032 1:CAS:528:DC%2BD2MXhslWrs7k%3D
30. DE Gomez DF Alonso H Yoshiji, et al. 1997 Tissue inhibitors of metalloproteinases: structure, regulation and biological functions Eur J Cell Biol 74 111 122 9352216 1:CAS:528:DyaK2sXmslSqsLg%3D
31. H Birkedal-Hansen WG Moore MK Bodden, et al. 1993 Matrix metalloproteinases: a review Crit Rev Oral Biol Med 4 197 250 8435466 1:STN:280:DyaK3s7mvVyhtw%3D%3D
32. E Lambert E Dasse B Haye, et al. 2004 TIMPs as multifacial proteins Crit Rev Oncol Hematol 49 187 198 15036259
33. AY Strongin I Collier G Bannikov, et al. 1995 Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease J Biol Chem 270 5331 5338 7890645 1:CAS:528: DyaK2MXksVSlur4%3D
34. SJ Atkinson T Crabbe S Cowell, et al. 1995 Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes J Biol Chem 270 30479 30485 8530478 1:CAS:528:DyaK28XhtFKnsg%3D%3D
35. HF Bigg CJ Morrison GS Butler, et al. 2001 Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase Cancer Res 61 3610 3618 11325829 1:CAS:528:DC%2BD3MXjsFCgtb4%3D
36. JL English Z Kassiri I Koskivirta, et al. 2006 Individual Timp deficiencies differentially impact pro-MMP-2 activation J Biol Chem 281 10337 10346 16469749 1:CAS:528:DC%2BD28Xjt1Kns70%3D
37. YE Liu M Wang J Greene, et al. 1997 Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4) J Biol Chem 272 20479 20483 9252358 1:CAS:528:DyaK2sXlsFKrsrg%3D
38. V Kandalam R Basu T Abraham, et al. 2010 TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation Circ Res 106 796 808 20056917 1:CAS:528:DC%2BC3cXivV2ksLg%3D
39. S Hernandez-Barrantes Y Shimura PD Soloway, et al. 2001 Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP Biochem Biophys Res Commun 281 126 130 11178970 1:CAS:528:DC%2BD3MXhtFemtr4%3D
40. M Kashiwagi M Tortorella H Nagase, et al. 2001 TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5) J Biol Chem 276 12501 12504 11278243 1:CAS:528:DC%2BD3MXjtFyntr0%3D
41. K Brew H Nagase 2010 The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Biochim Biophys Acta 1803 55 71 20080133 1:CAS:528:DC%2BC3cXitVKitLo%3D
42. F Loechel JW Fox G Murphy, et al. 2000 ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3 Biochem Biophys Res Commun 278 511 515 11095942 1:CAS:528:DC%2BD3cXotlalt7w%3D
43. M Wisniewska P Goettig K Maskos, et al. 2008 Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex J Mol Biol 381 1307 1319 18638486 1:CAS:528:DC%2BD1cXps1KjsL0%3D
44. A Amour PM Slocombe A Webster, et al. 1998 TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3 FEBS Lett 435 39 44 9755855 1:CAS:528: DyaK1cXmtlSitb4%3D
45. M Asakura M Kitakaze S Takashima, et al. 2002 Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy Nat Med 8 35 40 11786904 1:CAS:528: DC%2BD38Xjtlyhug%3D%3D
46. RA Black CT Rauch CJ Kozlosky, et al. 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 729 733 9034190 1:CAS:528:DyaK2sXhsVGktLs%3D
47. DC Lee SW Sunnarborg CL Hinkle, et al. 2003 TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase Ann N Y Acad Sci 995 22 38 12814936 1:CAS:528:DC%2BD3sXlsVegu7c%3D
48. Z Kassiri GY Oudit O Sanchez, et al. 2005 Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice Circ Res 97 380 390 16037568 1:CAS:528:DC%2BD2MXntlSiuro%3D
49. DS Smookler FF Mohammed Z Kassiri, et al. 2006 Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation J Immunol 176 721 725 16393953 1:CAS:528:DC%2BD28Xht1Crtw%3D%3D
50. Z Kassiri GY Oudit V Kandalam, et al. 2009 Loss of TIMP3 enhances interstitial nephritis and fibrosis J Am Soc Nephrol 20 1223 1235 19406980 1:CAS:528:DC%2BD1MXnvF2qsLc%3D
51. IM Clark TE Swingler CL Sampieri, et al. 2008 The regulation of matrix metalloproteinases and their inhibitors Int J Biochem Cell Biol 40 1362 1378 18258475 1:CAS:528:DC%2BD1cXlslGlu7o%3D
52. WH Yu S Yu Q Meng, et al. 2000 TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix J Biol Chem 275 31226 31232 10900194 1:CAS:528:DC%2BD3cXntlCisb4%3D
53. CJ Schulze W Wang WL Suarez-Pinzon, et al. 2003 Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury Circulation 107 2487 2492 12707244 1:CAS:528:DC%2BD3sXjs1antL0%3D
54. Z Kadri E Petitfrere C Boudot, et al. 2000 Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways Cell Growth Differ 11 573 580 11095246 1:CAS:528:DC%2BD3cXot1Grtb8%3D
55. WQ Li HY Qureshi A Liacini, et al. 2004 Transforming growth factor Beta1 induction of tissue inhibitor of metalloproteinases 3 in articular chondrocytes is mediated by reactive oxygen species Free Radic Biol Med 37 196 207 15203191
56. Y Hoshino T Mio S Nagai, et al. 2001 Fibrogenic and inflammatory cytokines modulate mRNA expressions of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-3 in type II pneumocytes Respiration 68 509 516 11694815 1:CAS:528:DC%2BD3MXotlWqu7o%3D
57. S Heymans B Schroen P Vermeersch, et al. 2005 Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart Circulation 112 1136 1144 16103240 1:CAS:528:DC%2BD2MXnvFyltbg%3D
58. J Fielitz M Leuschner HR Zurbrugg, et al. 2004 Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis J Mol Med 82 809 820 15558223 1:CAS:528: DC%2BD2cXhtVOqsL3I
59. V Polyakova S Miyagawa Z Szalay, et al. 2008 Atrial extracellular matrix remodelling in patients with atrial fibrillation J Cell Mol Med 12 189 208 18194448 1:CAS:528:DC%2BD1cXltlSqsrg%3D
60. H Kim T Oda J Lopez-Guisa, et al. 2001 TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy J Am Soc Nephrol 12 736 748 11274235 1:CAS:528:DC%2BD3MXjtVWgtrg%3D
61. Kassiri Z, Oudit G, Kandalam V et al. (2009) Loss of TIMP3 enhances TNFα and matrix metalloproteinase-mediated interstitial nephritis. J Am Assoc Nephrol (accepted)
62. ZD Zhong K Hammani WS Bae, et al. 2000 NF-Y and Sp1 cooperate for the transcriptional activation and cAMP response of human tissue inhibitor of metalloproteinases-2 J Biol Chem 275 18602 18610 10764764 1:CAS:528: DC%2BD3cXktlylsL0%3D
63. K Tanaka Y Iwamoto Y Ito, et al. 1995 Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080 Cancer Res 55 2927 2935 7796421 1:CAS:528:DyaK2MXmsFyksbw%3D
64. OL Buzzio Z Lu CD Miller, et al. 2006 FOXO1A differentially regulates genes of decidualization Endocrinology 147 3870 3876 16690806 1:CAS:528:DC%2BD28XnsVWms7g%3D
65. IM Clark AD Rowan DR Edwards, et al. 1997 Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1 Biochem J 324 Pt 2 611 617 9182725 1:CAS:528:DyaK2sXjvFGktrk%3D
66. K Hammani A Blakis D Morsette, et al. 1996 Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene J Biol Chem 271 25498 25505 8810321 1:CAS:528:DyaK28Xmt1emurs%3D
67. Y Sun G Hegamyer H Kim, et al. 1995 Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation J Biol Chem 270 19312 19319 7642607 1:CAS:528:DyaK2MXnsFyhu7c%3D
68. DA Young BW Phillips C Lundy, et al. 2002 Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene Biochem J 364 89 99 11988080 1:CAS:528:DC%2BD38XktFWiu7o%3D
69. PD Zamore B Haley 2005 Ribo-gnome: the big world of small RNAs Science 309 1519 1524 16141061 1:CAS:528:DC%2BD2MXpsFWisrg%3D
70. V Ambros 2004 The functions of animal microRNAs Nature 431 350 355 15372042 1:CAS:528:DC%2BD2cXnsFaiu7g%3D
71. M Garofalo G Di Leva G Romano, et al. 2009 miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation Cancer Cell 16 498 509 19962668 1:CAS:528:DC%2BC3cXht1eqsbk%3D
72. Song B, Wang C, Liu J et al. (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29
73. H Liu SE Chen B Jin, et al. 2010 TIMP3: a physiological regulator of adult myogenesis J Cell Sci 123 2914 2921 20682640 1:CAS:528:DC%2BC3cXhtlars7jN
74. Z Kassiri R Khokha 2005 Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors Thromb Haemost 93 212 219 15711735 1:CAS:528:DC%2BD2MXhs1Kgu7o%3D
75. F Zannad P Rossignol W Iraqi 2010 Extracellular matrix fibrotic markers in heart failure Heart Fail Rev 15 319 329 19404737 1:CAS:528: DC%2BC3cXns1Clur8%3D
76. R Martos J Baugh M Ledwidge, et al. 2009 Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover Eur J Heart Fail 11 191 197 19168518 1:CAS:528: DC%2BD1MXjvFOrt7w%3D
77. J Diez R Querejeta B Lopez, et al. 2002 Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients Circulation 105 2512 2517 12034658 1:CAS:528:DC%2BD38XkvFehu7g%3D
78. H Izawa T Murohara K Nagata, et al. 2005 Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2940 2945 16275882 1:CAS:528:DC%2BD2MXhtFKqtrvI
79. SH Poulsen NB Host SE Jensen, et al. 2000 Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction Circulation 101 1527 1532 10747345 1:CAS:528:DC%2BD3cXivVyhsbY%3D
80. Manhenke C, Orn S, Squire I et al. (2010) The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol (Epub ahead of print May 2010)
81. BI Jugdutt MJ Joljart MI Khan 1996 Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models Circulation 94 94 101 8964124 1:CAS:528:DyaK28XkslWru7k%3D
82. CS Webb DD Bonnema SH Ahmed, et al. 2006 Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling Circulation 114 1020 1027 16923753 1:CAS:528:DC%2BD28XoslOntr0%3D
83. AC Pouleur E Barkoudah H Uno, et al. 2010 Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both Circulation 122 597 602 20660803
84. BI Jugdutt 2010 Preventing adverse remodeling and rupture during healing after myocardial infarction in mice and humans Circulation 122 103 105 20585006
85. V Kandalam R Basu T Abraham, et al. 2010 Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction Am J Physiol Heart Circ Physiol 299 H1012 H1023 20675565 1:CAS:528:DC%2BC3cXhtlKltbrF
86. Y Yang Y Ma W Han, et al. 2008 Age-related differences in postinfarct left ventricular rupture and remodeling Am J Physiol Heart Circ Physiol 294 H1815 H1822 18263717 1:CAS:528:DC%2BD1cXkvVylu7s%3D
87. D Kelly SQ Khan M Thompson, et al. 2008 Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur Heart J 29 2116 2124 18614523
88. D Kelly IB Squire SQ Khan, et al. 2010 Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction Am J Cardiol 106 477 482 20691304 1:CAS:528:DC%2BC3cXpvVKmsbY%3D
89. YY Li AM Feldman Y Sun, et al. 1998 Differential expression of tissue inhibitors of metalloproteinases in the failing human heart Circulation 98 1728 1734 9788826 1:CAS:528:DyaK1cXnt1Kls74%3D
90. CM Tummalapalli BJ Heath SC Tyagi 2001 Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts J Cell Biochem 80 512 521 11169735 1:STN:280:DC%2BD3M3isV2hug%3D%3D
91. CV Thomas ML Coker JL Zellner, et al. 1998 Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy Circulation 97 1708 1715 9591765 1:STN:280:DyaK1c3lt1Cguw%3D%3D
92. YY Li Y Feng CF McTiernan, et al. 2001 Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices Circulation 104 1147 1152 11535571 1:CAS:528:DC%2BD3MXotlWnsbs%3D
93. Y Noji M Shimizu H Ino, et al. 2004 Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction Circ J 68 355 360 15056834 1:CAS:528:DC%2BD2cXjsVGgsLc%3D
94. PM Timms A Wright P Maxwell, et al. 2002 Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy Am J Hypertens 15 269 272 11939619 1:CAS:528:DC%2BD38XivFOksrs%3D
95. MM Lindsay P Maxwell FG Dunn 2002 TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension Hypertension 40 136 141 12154103 1:CAS:528:DC%2BD38XmtF2ktL0%3D
96. R Mukherjee AR Herron AS Lowry, et al. 2006 Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation Am J Cardiol 97 532 537 16461051 1:CAS:528:DC%2BD28XhtlaqtLw%3D
97. A Biolo S Ramamurthy LH LConnors, et al. 2008 Matrix Metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition Circulat Heart Failure 1 249 257 1:CAS:528:DC%2BD1cXhtlGmtbjO
98. PJ Barton EJ Birks LE Felkin, et al. 2003 Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure J Heart Lung Transplant 22 738 744 12873541
99. SC Tyagi S Kumar DJ Voelker, et al. 1996 Differential gene expression of extracellular matrix components in dilated cardiomyopathy J Cell Biochem 63 185 198 8913870 1:CAS:528:DyaK28XmslGju7s%3D
100. J Sundstrom JC Evans EJ Benjamin, et al. 2004 Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study Eur Heart J 25 1509 1516 15342170 1:CAS:528: DC%2BD2cXntlOhsro%3D
101. A Gonzalez B Lopez R Querejeta, et al. 2010 Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction Hypertension 55 1418 1424 20404218 1:CAS:528: DC%2BC3cXmt1alur0%3D
102. Zile MR, Desantis SM, Baicu CF et al. (2011) Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 4(3):246-256
103. Y Iwanaga T Aoyama Y Kihara, et al. 2002 Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats J Am Coll Cardiol 39 1384 1391 11955860 1:CAS:528:DC%2BD38XjsFait7w%3D
104. SE Gill SY Kassim TP Birkland, et al. 2010 Mouse models of MMP and TIMP function Methods Mol Biol 622 31 52 20135274 1:CAS:528:DC%2BC3cXoslyrtbY%3D
105. L Roten S Nemoto J Simsic, et al. 2000 Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice J Mol Cell Cardiol 32 109 120 10652195 1:CAS:528:DC%2BD3cXnsVSquw%3D%3D
106. EE Creemers JN Davis AM Parkhurst, et al. 2003 Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice Am J Physiol Heart Circ Physiol 284 H364 H371 12388239 1:CAS:528:DC%2BD3sXmvF2htg%3D%3D
107. JS Ikonomidis JW Hendrick AM Parkhurst, et al. 2005 Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition Am J Physiol Heart Circ Physiol 288 H149 H158 15598866 1:CAS:528:DC%2BD2MXhtVCqsb8%3D
108. Z Wang R Juttermann PD Soloway 2000 TIMP-2 is required for efficient activation of proMMP-2 in vivo J Biol Chem 275 26411 26415 10827175 1:CAS:528:DC%2BD3cXmt1OktL4%3D
109. Kandalam V, Basu R, Moore L et al. (2011) Lack of TIMP2 leads to exacerbated LV dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation Resubmitted (minor Revisions)
110. R Ramani K Nilles G Gibson, et al. 2011 Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling Clin Transl Sci 4 24 31 21348952 1:CAS:528:DC%2BC3MXjt1Wltbg%3D
111. PW Fedak DS Smookler Z Kassiri, et al. 2004 TIMP-3 deficiency leads to dilated cardiomyopathy Circulation 110 2401 2409 15262835 1:CAS:528: DC%2BD2cXosVSls7s%3D
112. Kassiri Z, Defamie V, Hariri M et al. (2009) Simultaneous TGFbeta-TNF activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in tissue inhibitor of metalloproteinase 3 deficient heart. J Biol Chem 284(43):29893-29904
113. H Tian M Cimini PW Fedak, et al. 2007 TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction J Mol Cell Cardiol 43 733 743 17945252 1:CAS:528:DC%2BD2sXhtlyrtbbL
114. Koskivirta I, Kassiri Z, Rahkonen O et al. (2010) Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 285:24487-24493
115. T Takahashi Y Hiasa Y Ohara, et al. 2008 Relationship of admission neutrophil count to microvascular injury, left ventricular dilation, and long-term outcome in patients treated with primary angioplasty for acute myocardial infarction Circ J 72 867 872 18503208
116. Papa A, Emdin M, Passino C et al. (2008) Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta 395(1-2):27-31
117. I Koskivirta Z Kassiri O Rahkonen, et al. 2010 Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload J Biol Chem 285 24487 24493 20516072 1:CAS:528:DC%2BC3cXpsFems7c%3D
118. DE Doherty PM Henson RA Clark 1990 Fibronectin fragments containing the RGDS cell-binding domain mediate monocyte migration into the rabbit lung. A potential mechanism for C5 fragment-induced monocyte lung accumulation J Clin Invest 86 1065 1075 2212000 1:CAS:528:DyaK3cXmtV2rtLc%3D
119. RM Senior GL Griffin RP Mecham 1980 Chemotactic activity of elastin-derived peptides J Clin Invest 66 859 862 6903189 1:CAS:528: DyaL3cXmtVamt7k%3D
120. S Matsumura S Iwanaga S Mochizuki, et al. 2005 Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice J Clin Invest 115 599 609 15711638 1:CAS:528: DC%2BD2MXit1emsbY%3D
121. TL Adair-Kirk RM Senior 2008 Fragments of extracellular matrix as mediators of inflammation Int J Biochem Cell Biol 40 1101 1110 18243041 1:CAS:528:DC%2BD1cXlslGltbg%3D
122. RA Clark NE Wikner DE Doherty, et al. 1988 Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment J Biol Chem 263 12115 12123 3403561 1:CAS:528: DyaL1cXlvVyhtL0%3D
123. KA Hance M Tataria SJ Ziporin, et al. 2002 Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor J Vasc Surg 35 254 261 11854722
124. P Van Lint C Libert 2006 Matrix metalloproteinase-8: cleavage can be decisive Cytokine Growth Factor Rev 17 217 223 16820317
125. Cuadrado E, Ortega L, Hernandez-Guillamon M et al. (2008) Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol 84(1):207-214
126. A Matsuda Y Itoh N Koshikawa, et al. 2003 Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils J Biol Chem 278 36350 36357 12860995 1:CAS:528:DC%2BD3sXnt1ejs7Y%3D
127. JM Lambert EF Lopez ML Lindsey 2008 Macrophage roles following myocardial infarction Int J Cardiol 130 147 158 18656272
128. SE Gill I Huizar EM Bench, et al. 2010 Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury Am J Pathol 176 64 73 20008147 1:CAS:528:DC%2BC3cXhs12rsbc%3D
129. D Vanhoutte S Heymans 2010 TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family' J Mol Cell Cardiol 48 445 453 19799912 1:CAS:528:DC%2BC3cXitVejurg%3D
130. R Chirco XW Liu KK Jung, et al. 2006 Novel functions of TIMPs in cell signaling Cancer Metastasis Rev 25 99 113 16680576 1:CAS:528: DC%2BD28Xktlaksro%3D
131. DW Seo H Li L Guedez, et al. 2003 TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism Cell 114 171 180 12887919 1:CAS:528:DC%2BD3sXlvFCgu7k%3D
132. WG Stetler-Stevenson DW Seo 2005 TIMP-2: an endogenous inhibitor of angiogenesis Trends Mol Med 11 97 103 15760767 1:CAS:528:DC%2BD2MXit1eqsrw%3D
133. G Lluri GD Langlois B McClellan, et al. 2006 Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism J Neurobiol 66 1365 1377 16967503 1:CAS:528:DC%2BD28Xht1WmsrjM
134. JH Qi Q Ebrahem N Moore, et al. 2003 A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 Nat Med 9 407 415 12652295 1:CAS:528:DC%2BD3sXisVOmu7k%3D
135. -/- mice leads to chronic hepatic inflammation and failure of liver regeneration Nat Genet 36 969 977 15322543 1:CAS:528:DC%2BD2cXntFSku74%3D
136. JD Lovelock AH Baker F Gao, et al. 2005 Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts Am J Physiol Heart Circ Physiol 288 H461 H468 15650153 1:CAS:528:DC%2BD2MXhsFemt7o%3D
137. T Hayakawa K Yamashita K Tanzawa, et al. 1992 Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum FEBS Lett 298 29 32 1544418 1:CAS:528:DyaK38Xit1yqsrk%3D
138. ML Corcoran WG Stetler-Stevenson 1995 Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism J Biol Chem 270 13453 13459 7768948 1:CAS:528:DyaK2MXmtV2hs7s%3D
139. AN Murphy EJ Unsworth WG Stetler-Stevenson 1993 Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation J Cell Physiol 157 351 358 7693724 1:CAS:528:DyaK2cXpsFE%3D
140. PT Wingfield JK Sax SJ Stahl, et al. 1999 Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions J Biol Chem 274 21362 21368 10409697 1:CAS:528:DyaK1MXkvVKrt7k%3D
141. TT Yang SP Hawkes 1992 Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts Proc Natl Acad Sci USA 89 10676 10680 1438264 1:CAS:528:DyaK3sXnslCltg%3D%3D
142. L Hammoud F Xiang X Lu, et al. 2007 Endothelial nitric oxide synthase promotes neonatal cardiomyocyte proliferation by inhibiting tissue inhibitor of metalloproteinase-3 expression Cardiovasc Res 75 359 368 17553475 1:CAS:528:DC%2BD2sXntFKgsro%3D
143. MY Celiker M Wang E Atsidaftos, et al. 2001 Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA Oncogene 20 4337 4343 11466614 1:CAS:528:DC%2BD3MXlvFOis7c%3D
144. R Zamilpa ML Lindsey 2010 Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences J Mol Cell Cardiol 48 558 563 19559709 1:CAS:528:DC%2BC3cXitVeisrw%3D
145. KR Hutchinson JA Stewart Jr PA Lucchesi 2009 Extracellular matrix remodeling during the progression of volume overload-induced heart failure J Mol Cell Cardiol 48 564 569 19524591
146. MP Hudson PW Armstrong W Ruzyllo, et al. 2006 Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial J Am Coll Cardiol 48 15 20 16814643 1:CAS:528:DC%2BD28XmtlGms70%3D
147. A Biolo S Ramamurthy LH Connors, et al. 2008 Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition Circ Heart Fail 1 249 257 19808299 1:CAS:528:DC%2BD1cXhtlGmtbjO
148. Johnson RR, Hapke E, Hendrick JW et al. (2002) Chronic pressure overload: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase type 1 (TIMP-1) on hypertrophic remodeling. Abs # 2125. Circulation Suppl 106:II-427